Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 214

Sort by

Sort Order Select

Journal Articles

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Monica S Nair, Sara K Silbert, Kai Rejeski, Karilynn A Wilson, Adam Joseph Lamble, Yannis K. Valtis, Bonnie Yates, Alexa Morales Arana, Roni Shouval, Kevin J. Curran, Rebecca A Gardner, Haneen Shalabi, Colleen Annesley, Jae H. Park, Marion Subklewe, Nirali N Shah

Blood blood.2024025910.

https://doi.org/10.1182/blood.2024025910

Published: 2024

Includes: Supplemental data

Journal Articles

CARdinal signs of variant ICANS

Juliane Gust, Nirali N. Shah

Blood (2024) 144 (13): 1352–1354.

https://doi.org/10.1182/blood.2024025664

Published: 2024

Journal Articles

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial

Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah, Catherine C. Coombs, Nirav N. Shah, William G. Wierda, Manish R. Patel, Nicole Lamanna, Donald E. Tsai, Binoj Nair, Chunxiao Wang, Xiang Zhao, Dan Liu, David Radtke, Sonya Chapman, Narasimha Marella, Samuel C. McNeely, Jennifer R. Brown

Blood (2024) 144 (13): 1374–1386.

https://doi.org/10.1182/blood.2024024510

Published: 2024

Includes: Supplemental data

Journal Articles

How I treat post-immunotherapy relapsed B-ALL

Adam J. Lamble, Alexandra E Kovach, Nirali N Shah

Blood blood.2024024517.

https://doi.org/10.1182/blood.2024024517

Published: 2024

Journal Articles

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Blood (2024) 143 (16): 1565–1575.

https://doi.org/10.1182/blood.2023022432

Published: 2024

Journal Articles

Impact of Treatment with Inotuzumab Ozogamicin before or after Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Lymphoblastic Leukemia

Susan R Rheingold, Lingyun Ji, Lia Gore, Xinxin Xu, Deepa Bhojwani, Nirali N. Shah, Elizabeth A. Raetz, Mignon L. Loh, Maureen M. O'Brien

Blood (2023) 142 (Supplement 1): 2876.

https://doi.org/10.1182/blood-2023-183103

Published: 2023

Journal Articles

Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study

Blood (2023) 142 (Supplement 1): 6535.

https://doi.org/10.1182/blood-2023-186145

Published: 2023

Journal Articles

Engineering Off-the-Shelf Gamma Delta CAR T Cells for the Treatment of Acute Myeloid Leukemia

Alka Dwivedi, Lynn Fu, Chris Daniel Chien, Marie Pouzolles, Nirali N. Shah, Naomi Taylor

Blood (2023) 142 (Supplement 1): 4827.

https://doi.org/10.1182/blood-2023-190357

Published: 2023

Journal Articles

Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS

Sara K. Silbert, Cynthia Harrison, D. Nathan Biery, Alexandra Semchenkova, Elena Zerkalenkova, Anna Alonso-Saladrigues, Kaylyn Utley, Ibrahim Aldoss, Liping Zhao, Sneha Fernandes, Jeremy D. Rubinstein, Naomi Torres Carapia, Bill H. Chang, Anant Vatsayan, Barbara De Moerloose, Holly L. Pacenta, Dennis John Kuo, Gabriele Escherich, Benjamin J. Lee, Michele S. Redell, Mandi R. Fitzjohn, Daniel P. Larson, Nicolas Duployez, Raymund S. Cuevo, Rui Rochelle He, David Dickens, Firas El Chaer, Kelly Reed, Matthias Wolfl, Sunil S. Raikar, Süreyya Savaşan, Latika Puri, Zhubin J. Gahvari, Aimee C. Talleur, Hisham Abdel-Azim, Aghiad Chamdin, Marlie R.M. Provost, Vanessa A. Fabrizio, Kerstin Mezger, Alexandra McLean Stevens, Emily M. Hsieh, Hao-Wei Wang, Constance M. Yuan, Ulrich A. Duffner, Jing Pan, Sara Ghorashian, Susana Rives, Chloe Hoang, Kara L. Davis, Elad Jacoby, Alexander Popov, Adam Lamble, Nirali N. Shah

Blood (2023) 142 (Supplement 1): 4202.

https://doi.org/10.1182/blood-2023-182293

Published: 2023

Journal Articles

Generation of Hinge-Modified Human CD19 Chimeric Antigen Receptor (CAR) T Cells for the Treatment of CD19-Low Leukemia

Victoria M. Giordani, Justin Mirazee, Marie Pouzolles, Mehdi Benzaoui, Chris Daniel Chien, Saliha Majdoul, Sooraj Achar, Adam Kenet, Madison Wahlsten, Gregoire Altan-Bonnet, James N Kochenderfer, Nirali N. Shah, Taisuke Kondo, Naomi Taylor

Blood (2023) 142 (Supplement 1): 6819.

https://doi.org/10.1182/blood-2023-187954

Published: 2023

Journal Articles

Itacitinib for the Prevention of Immune Effector Cell Therapy-Associated Cytokine Release Syndrome: Results from the Phase 2 Incb 39110-211 Placebo-Controlled Randomized Cohort

Matthew J. Frigault, Richard T Maziarz, Jae H. Park, Aleksandr Lazaryan, Nirav N. Shah, Jakub Svoboda, Lazaros J. Lekakis, Ran Reshef, Christine L Phillips, Lea M Burke, Jing Lei, Rodica Morariu-Zamfir, John F. DiPersio

Blood (2023) 142 (Supplement 1): 356.

https://doi.org/10.1182/blood-2023-180205

Published: 2023

Journal Articles

Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study

Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah, Catherine C Coombs, Nirav N. Shah, William G. Wierda, Manish Patel, Donald E. Tsai, Binoj Nair, Chunxiao Wang, Xiang Zhao, Narasimha Marella, Caleb Ho, Samuel McNeely, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 3269.

https://doi.org/10.1182/blood-2023-181090

Published: 2023

Journal Articles

Engraftment Syndrome during Autologous Stem Cell Transplant in Hodgkin Lymphoma Patients Treated with Checkpoint Inhibitors: A Multi-Center Retrospective Analysis

Eleanor Taranto, Wei-Ting Hwang, Maria Alfaro, Annika S Surapaneni, Sarvarinder Kaur Gill, Tatyana Feldman, Michael P Randall, Michael A Spinner, Fateeha Furqan, Nirav N. Shah, Yazeed Samara, Matthew G. Mei, Alex F. Herrera, Alison Moskowitz, Gunjan L. Shah, Jakub Svoboda

Blood (2023) 142 (Supplement 1): 3603.

https://doi.org/10.1182/blood-2023-187199

Published: 2023

Journal Articles

Multicenter Study to Assess the Outcomes and Prognosis of Richter's Transformation in the Era of Novel Agents and Cell Therapy

Fateeha Furqan, Katelin Baird, Merve Kacar, Annika S Surapaneni, Ulrich Kemmo Tsafack, Aniko Szabo, Jakub Svoboda, Brian T. Hill, Jason T. Romancik, Nirav N. Shah

Blood (2023) 142 (Supplement 1): 4486.

https://doi.org/10.1182/blood-2023-186703

Published: 2023

Journal Articles

Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Nitin Jain, James D'Olimpio, Andew gillis-Smith, Seung Tae Lee, Nirav N. Shah, Javier Pinilla-Ibarz, Catherine C. Coombs, Jacqueline C. Barrientos, Shuo Ma, Masaaki Sawa, Kyoko Miyamoto, Akinori Arimura, Varsha Gandhi, William G. Wierda

Blood (2023) 142 (Supplement 1): 3288.

https://doi.org/10.1182/blood-2023-182568

Published: 2023

Journal Articles

CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial

Blood (2023) 142 (Supplement 1): 771.

https://doi.org/10.1182/blood-2023-179667

Published: 2023

Journal Articles

Exploration of Language As a Barrier to the Assessment and Management of CAR T-Cell Therapy Associated Toxicities

Blood (2023) 142 (Supplement 1): 2407.

https://doi.org/10.1182/blood-2023-183041

Published: 2023

Journal Articles

Adaptive Manufacturing of LV20.19 CAR T-Cells for Relapsed, Refractory Mantle Cell Lymphoma

Nirav N. Shah, Fateeha Furqan, Aniko Szabo, Tyce Kearl, Anthony Zamora, Jessica Neumann, Parameswaran N. Hari, Dina Schneider, Walter Longo, Peiman Hematti, Bryon D. Johnson, Mehdi Hamadani, Timothy S. Fenske

Blood (2023) 142 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2023-173954

Published: 2023

Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 3026.

https://doi.org/10.1182/blood-2023-181309

Published: 2023

Journal Articles

Immune Reconstitution and Infection Patterns Following CAR T-Cell Therapy in Patients with Aggressive Lymphoma

Blood (2023) 142 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2023-183011

Published: 2023

NARROW

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

CARdinal signs of variant ICANS

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial

How I treat post-immunotherapy relapsed B-ALL

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Impact of Treatment with Inotuzumab Ozogamicin before or after Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Lymphoblastic Leukemia

Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study

Engineering Off-the-Shelf Gamma Delta CAR T Cells for the Treatment of Acute Myeloid Leukemia

Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS

Generation of Hinge-Modified Human CD19 Chimeric Antigen Receptor (CAR) T Cells for the Treatment of CD19-Low Leukemia

Itacitinib for the Prevention of Immune Effector Cell Therapy-Associated Cytokine Release Syndrome: Results from the Phase 2 Incb 39110-211 Placebo-Controlled Randomized Cohort

Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study

Engraftment Syndrome during Autologous Stem Cell Transplant in Hodgkin Lymphoma Patients Treated with Checkpoint Inhibitors: A Multi-Center Retrospective Analysis

Multicenter Study to Assess the Outcomes and Prognosis of Richter's Transformation in the Era of Novel Agents and Cell Therapy

Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial

Exploration of Language As a Barrier to the Assessment and Management of CAR T-Cell Therapy Associated Toxicities

Adaptive Manufacturing of LV20.19 CAR T-Cells for Relapsed, Refractory Mantle Cell Lymphoma

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

Immune Reconstitution and Infection Patterns Following CAR T-Cell Therapy in Patients with Aggressive Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only